Virtus ETF Advisers’s Aprea Therapeutics APRE Stock Holding History

Virtus ETF Advisers’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-523	Closed	-$53K	–	400
2021 Q1	$53K	Buy	523 +10	+2%	+$1.17K	0.02%	355
2020 Q4	$50K	Buy	513 +11	+2%	+$5.23K	0.02%	353
2020 Q3	$242K	Sell	502 -70	-12%	-$39.2K	0.13%	273
2020 Q2	$443K	Buy	+572	New	+$375K	0.21%	167

Other funds holding APRE

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Virtus ETF Advisers's APRE Position: Q2 2021 in Review

Virtus ETF Advisers sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 523 shares — an estimated $53K sold.

Virtus ETF Advisers first reported a position in APRE in Q2 2020 and held it in 4 quarters. The position peaked at $443K in Q2 2020. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

Virtus ETF Advisers reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
Virtus ETF Advisers sold 523 Aprea Therapeutics shares in Q2 2021, an estimated $53K.
Virtus ETF Advisers first reported a position in Aprea Therapeutics in Q2 2020 and held it in 4 quarters.
Virtus ETF Advisers's Aprea Therapeutics position peaked at $443K in Q2 2020.
50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.